Zobrazeno 1 - 10
of 30
pro vyhledávání: '"V. A. Bhadkamkar"'
Autor:
Terrie G. Gornet, John W. Davis, Hiroyuki Nakanishi, Vikas Kumar, V. A. Bhadkamkar, R. Joseph Babaian, Herbert A. Fritsche, Beverly Carol Handy, Robert McCormack
Publikováno v:
Journal of Urology. 179:2187-2191
We evaluated the hypothesis that circulating tumor cells as determined using the CellSearch System would correlate with tumor volume, pathological stage and Gleason score in men with localized prostate cancer.Samples of blood (30 ml) were drawn from
Autor:
John W. Davis, Hiroyuki Nakanishi, Harry G. Rittenhouse, Amy Blase, Jack Groskopf, Patricia Troncoso, V. A. Bhadkamkar, S. Vikas Kumar, Herbert A. Fritsche, R. Joseph Babaian
Publikováno v:
Journal of Urology. 179:1804-1810
Purpose: Prostate cancer gene 3 (PCA3) has shown promise as a molecular marker in prostate cancer detection. We assessed the association of urinary PCA3 score with prostatectomy tumor volume and other clinical and pathological features.Materials and
Autor:
John W. Davis, R. Joseph Babaian, Herbert A. Fritsche, Ashish Shukla, V. A. Bhadkamkar, Atsushi Ochiai
Publikováno v:
Urology. 70:519-522
Objectives To retrospectively evaluate the diagnostic performance of a serum human tissue kallikrein 11 (hK11) assay to predict the presence of prostate cancer in a screened population of men with a total prostate-specific antigen (PSA) level between
Autor:
Sirisriro R, V. A. Bhadkamkar, L. P. Kasi, Euishin E. Kim, Donald A. Podoloff, Yehuda Z. Patt, R. smith, T. P. Haynie, Steven A. Curley, James L. Murray
Publikováno v:
Nuclear Medicine Communications. 17:568-576
The aims of this study were to evaluate the efficacy of scintigraphy with the 99 Tc m -labelled anti-carcinoembryonic antigen (CEA) monoclonal antibody Fab' fragment (IMMU4) in the diagnosis of recurrent colorectal carcinoma and to investigate its us
Autor:
V. A. Bhadkamkar, Hua‐Zhong ‐Z Zhang, Joan E. Cunningham, Donald A. Podoloff, L. P. Kasi, Daniel J. Macey, James L. Murray, Paula Trahan Rieger, Michael G. Rosenblum, Jeffrey Schlom
Publikováno v:
Cancer. 73:1057-1066
Background. Radiolabeled CC49, a second generation high affinity monoclonal antibody (MoAb) reactive with tumor-associated glycoprotein 72 (TAG72) has undergone previous Phase I testing in patients with colon cancer. Based on this report, the authors
Autor:
James L. Murray, L. P. Kasi, Kalpana Mujoo, Robert S. Benjamin, Herbert A. Fritsche, Alexander Zukiwski, Donald A. Podoloff, Hannah Brewer, Joan E. Cunningham, V. A. Bhadkamkar
Publikováno v:
Journal of Clinical Oncology. 12:184-193
PURPOSE The purpose of this phase I trial was to determine the toxicity and maximum-tolerated dose (MTD) of murine monoclonal antibody (Mab) 14G2a (anti-GD2) in cancer patients. PATIENTS AND METHODS Following tracer doses of iodine-131-labeled 14G2a
Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer
Autor:
V. A. Bhadkamkar, Richard J. Babaian, Stephen D. Mikolajczyk, Harry G. Rittenhouse, Herbert A. Fritsche, Yoshio Naya
Publikováno v:
Urologic oncology. 23(1)
Objective Disease-associated isoforms of the prostate-specific antigen (PSA) have recently been identified. We evaluated the efficacy of using precursor isoforms of PSA (pPSA) and their ratios for the detection of prostate cancer. Methods Serum conce
Autor:
Harry G. Rittenhouse, V. A. Bhadkamkar, R. Joseph Babaian, Yoshio Naya, Stephen D. Mikolajczyk, Herbert A. Fritsche
Publikováno v:
Urology. 63(3)
Recently, disease-specific isoforms of the prostate-specific antigen (PSA) have been identified. We evaluated the efficacy of precursor isoforms of PSA (pPSA) and an internally cleaved form of PSA referred to as the benign prostatic hyperplasia-assoc
Publikováno v:
Cancer. 91(8)
A variable biochemical failure rate has been reported for patients undergoing radical prostatectomy. The authors analyzed their 1987-1993 prostatectomy experience retrospectively to stratify the risk of failure in order to appropriately select patien
Publikováno v:
The Journal of urology. 165(3)
It has recently been suggested that the diagnostic threshold for the prostate specific antigen (PSA) assay be lowered to enhance prostate cancer detection. A 22% incidence of prostate cancer has been reported in men with PSA between 2.5 and 4.0 ng/ml